quote:

---

Originally posted by machtabow:
EASY PLAY. BOUNCING INTO CLOSE AND HUGE AT TOMMORROWS OPEN. MACH

---

quote:

---

Originally posted by machtabow:
EASY PLAY. BOUNCING INTO CLOSE AND HUGE AT TOMMORROWS OPEN. MACH

---

quote:

---

Originally posted by knee-hi-boot-gurl:
okay, now I know it will tank! thanks for the confermation!

---

What's that supposed to mean? lol... um

Safescript Pharmacies, Inc. Announces and Addresses SEC Investigation; Edward Dmytryk Appointed Interim CEO 2/3/2004 9:36:57 AM

LONGVIEW, Texas, Feb 03, 2004 /PRNewswire-FirstCall via Comtex/ -- Safescript Pharmacies, Inc. ( SAFS ) announced that it has been notified that the Securities and Exchange Commission may commence an enforcement action against the Company and certain executive officers for alleged violation of the Securities Act of 1933 and the Securities Exchange Act of 1934. The Company believes that the investigation arose principally from the past recognition of revenue from sales of certain market territories. The Company is cooperating fully with the SEC in its investigation and has appointed a committee, consisting exclusively of independent directors, to fully investigate these matters.

Safescript's Board of Directors accepted the resignations of Mr. Curtis Swanson, the Chief Executive Officer and a Director, Mr. Steve Cavender, the Chief Financial Officer, and Mr. Curtis Borman, a Director and a market partner of the Company. The Board of Directors has appointed Mr. Ed Dmytryk CEO and has elected Mr. Dmytryk and Dr. Kenneth Reesor to fill the vacancies on the Board of Directors. Dr. Reesor and Mr. Gilliam, an existing Director, were appointed to the independent committee responsible for the investigation of these matters. The Company does not currently have Director and Officer insurance.

Mr. Dmytryk has been involved in numerous public and private restructuring, transition and compliance assignments since 1980. Prior to joining Safescript, Mr. Dmytryk was a member of the board of directors and the acting CFO of Park City Group, Inc., a public spin-off from Fields Cookies, Inc., responsible for bringing the company into compliance with federal reporting requirements following its restructure. In July 2003, Mr. Dmytryk joined Safescript to oversee the integration of the Medex Pegasus acquisition and again to oversee the recent merger of Advanced Pharmacy Solutions, Inc. During his 6-month tenure at Safescript, Mr. Dmytryk has been directly responsible for the divisions that represent more than 75 percent of the Company's current revenues.

Dr. Kenneth Reesor is an orthopedic surgeon based in Longview, Texas. He was the first healthcare professional to adopt the use of the Safescript technology and regularly uses the Safescript system to transmit prescriptions to the Longview, Texas, pharmacy owned by the Company.

Safescript Pharmacies, Inc. (f/k/a RTIN Holdings, Inc.) is a medical communications technology company that has developed a proprietary wireless communication system for transmitting prescription medication scripts from healthcare professionals to a dedicated pharmacy. During 2001 and 2002, the majority of revenues reported by the Company were attributed to the sale of territories to investors who were licensed to use the proprietary technology within the territory in exchange for a one-time license fee, an agreement to pay a per store assistance fee, and a royalty fee based on the gross revenues of pharmacies operated by the investor.

During 2003, the Company transitioned from generating the majority of its revenue from license fees through the sale of market territories to producing revenue from operating company-owned pharmacies. Since the beginning of 2003, Safescript Pharmacies, Inc. grew from three company-owned pharmacies to 15 company-owned and 6 market partner-owned pharmacies today. During this period, membership expanded from 10 prescribing doctors and 765 patients to 349 prescribing doctors (with 40 additional doctors in queue) and over 76,000 patients. Total prescriptions filled by Safescript pharmacies during the month of January 2004 aggregated nearly 36,000 compared to 3,700 in January 2003. Moreover, as the Company fully integrates its recent acquisition of Advanced Pharmacy Solutions, an additional 485 prescribing physicians will be added on the SafeMed system. The Company has reported six quarters of consistent sequential revenue growth from its company-owned pharmacies. Revenue from its company-owned pharmacies has grown from $107,550 during the second quarter of 2002, when if first started generating revenue from this source, to $4.8 million during its most recently reported quarter ended September 2003.

quote:

---

Originally posted by machtabow:
EASY PLAY. BOUNCING INTO CLOSE AND HUGE AT TOMMORROWS OPEN. MACH

---

quote:

---

Originally posted by rde3:
Mach, still think SAFS is going to $4 ?

---

quote:

---

Originally posted by dardadog:
Nice play MACH.

---

quote:

---

Originally posted by tigerontop:
Im in! BB's are getting tighter....primed for another run.

---

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden
hours per response 0.5



Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*ELAN CORP PLC

--------------------------------------------------------------------------------
(Last) (First) (Middle)
LINCOLN HOUSE, LINCOLN PLACE

--------------------------------------------------------------------------------
(Street)DUBLIN 2 L2

--------------------------------------------------------------------------------
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
GLYCOGENESYS INC [GLGS] 5. Relationship of Reporting Person(s) to Issuer
(Check all applicable) Director X 10% Owner
Officer (give title below) Other (specify below)


3. Date of Earliest Transaction (Month/Day/Year)
02/03/2004
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person
X Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8) 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4) 7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/03/2004 S 20,000 D $ 1.26 2,723,906 I (1) I (1)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date
(Month/Day/Year) 7. Title and Amount of Underlying Securities
(Instr. 3 and 4) 8. Price of Derivative Security
(Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4) 11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Reporting Owner Name / AddressM Relationships
Director 10% Owner Officer Other
ELAN CORP PLC
LINCOLN HOUSE
LINCOLN PLACE
DUBLIN 2, L2 X
ELAN INTERNATIONAL SERVICES LTD
102 JAMES COURT FLATTS
SMITH PARISH FL 04
BERMUDA, D0 00000 X
Explanation of Responses:
1. These securities are beneficially owned indirectly by Elan Corporation, plc and directly by its wholly-owned subsidiary, Elan International Services, Ltd.

Remarks:
Exhibit List - Exhibit 99 - Joint Filer Information
/s/ William F. Daniel, Executive Vice President and Secretary, ELAN CORPORATION, PLC 02/05/2004
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

--------------------------------------------------------------------------------

Exhibit 99
Joint Filer Information
Name: Elan International Services, Ltd.
Address: 102 St. James Court
Flatts, Smiths FL 04
Bermuda
Designated Filer: Elan Corporation, plc
Issuer & Ticker Symbol: GlycoGenesys, Inc. (GLGS)
Date of Earliest
Transaction Required
to be Reported: 2/3/04
Signature: /s/ Kevin Insley
Name: Kevin Insley
Title: President and Chief Financial Officer
Page 3 of 3

THI JUST OUT

quote:

---

Originally posted by dardadog:
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden
hours per response 0.5



Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*ELAN CORP PLC

---